India invests least on drug discovery
Advertisement
Healthcare risk in India has been on a rise, with the disease burden trends increasing. However, not enough is being done in terms of funding and investment by the country to reduce its dependence on imports for healthcare products.
Consider this; India's per capita expenditure on health research is less than $1. More meager is the figure of 3% which is spent on public health, which forms the backbone of the healthcare risk issue which India continues to tackle.
As further implied in a statement to TOI, Indian Council for Medical Research (ICMR) director general Dr Soumya Swaminathan said that the government must work towards achieving maximum product development capability, and spent most of it on the public health expenditure. This can be further ensured with expanding clinical trial network and, by focusing on multi centric trials.
Again, proven statistically, India has the least investment in healthcare research (drug discovery) of 30% compared to other countries such as Japan, US, and Germany. The call of the time is to invest more resources and invest in high risk long term research to utilise the big potential in India.
Consider this; India's per capita expenditure on health research is less than $1. More meager is the figure of 3% which is spent on public health, which forms the backbone of the healthcare risk issue which India continues to tackle.
As further implied in a statement to TOI, Indian Council for Medical Research (ICMR) director general Dr Soumya Swaminathan said that the government must work towards achieving maximum product development capability, and spent most of it on the public health expenditure. This can be further ensured with expanding clinical trial network and, by focusing on multi centric trials.
Again, proven statistically, India has the least investment in healthcare research (drug discovery) of 30% compared to other countries such as Japan, US, and Germany. The call of the time is to invest more resources and invest in high risk long term research to utilise the big potential in India.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.